– USA, CA – Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced the appointment of Joshua Murray to its Board of Directors.
Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of the stress hormone cortisol.
“I am very pleased to welcome Josh to our board,” said CEO, Dr. Joseph Belanoff. “His extensive experience counseling healthcare companies confronting the challenges and opportunities of growth will help us as we bring Korlym to more patients and advance our pipeline of proprietary, selective cortisol modulators.”
About Joshua Murray
Joshua Murray is currently SVP, Finance, Strategy, and Investor Relations at Orca Bio, a privately held biotechnology company developing allogeneic cell therapies in blood, immune, and genetic diseases. Before joining Orca, Mr. Murray spent 15 years at Goldman Sachs, most recently as a Managing Director in the Investment Banking Division, where he advised a wide array of biotechnology and life sciences companies. He received an AB in History and Economics from Harvard College.
About Corcept Therapeutics
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
For more information: https://www.corcept.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.